0000000000524666

AUTHOR

F. Giancola

showing 5 related works from this author

Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study

2017

Objectives: Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of bisphosphonates (BP). Although the risk of ONJ increases with increasing duration of BP treatment, there are currently no reliable estimates of the ONJ time to onset (TTO). The objective of this study was to estimate the TTO and associated risk factors in BP-treated patients. Subjects and Methods: Retrospective analysis of data from 22 secondary care centres in seven countries relevant to 349 patients who developed BP-related ONJ between 2004 and 2012. Results: The median (95%CI) TTO was 6.0 years in patients treated with alendronate (n = 88) and 2.2 years in those treated with zoledronate (n = 218). Multiv…

MalebisphosphonateTime Factorsmedicine.medical_treatmentOsteoporosis0302 clinical medicineRisk Factors80 and overosteoporosijaw osteonecrosiAged 80 and overBone Density Conservation AgentsDiphosphonatesjaw osteonecrosisjaw osteonecrosis bisphosphonates breast cancer multiple myeloma prostate cance osteoporosisIncidenceIncidence (epidemiology)Otorhinolaryngology2734 Pathology and Forensic MedicineMiddle Agedprostate cancermultiple myeloma030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawFemaleAdultmedicine.medical_specialty2734Drug Administration SchedulePathology and Forensic Medicine03 medical and health sciencesbreast cancerbisphosphonates; breast cancer; jaw osteonecrosis; multiple myeloma; osteoporosis; prostate cancer; Adult; Aged; Aged 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cross-Sectional Studies; Diphosphonates; Drug Administration Schedule; Female; Humans; Incidence; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Otorhinolaryngology; 2734; Pathology and Forensic Medicine; Dentistry (all)Internal medicinemedicineHumansBisphosphonates; Breast cancer; Jaw osteonecrosis; Multiple myeloma; Osteoporosis; Prostate cancer; Otorhinolaryngology2734 Pathology and Forensic Medicine; Dentistry (all)prostate canceAdverse effectGeneral DentistrybisphosphonatesAgedProportional Hazards ModelsRetrospective StudiesBisphosphonate-associated osteonecrosis of the jawbusiness.industryProportional hazards modelRetrospective cohort study030206 dentistryBisphosphonatemedicine.diseaseosteoporosisSurgeryCross-Sectional StudiesOtorhinolaryngologyMultivariate AnalysisDentistry (all)businessOsteonecrosis of the jaw
researchProduct

BRONJ in patients with rheumatoid arthritis: A multicenter case series

2016

Objective: Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of various medications (bisphosphonates, anti-resorptive, and anti-angiogenic drugs). ONJ pathogenesis is still unclear although some risk factors have been recognized. Of these, rheumatoid arthritis (RA) has been hypothesized as a potential risk factor for developing ONJ. This observational study will describe a multicenter case series of patients affected with RA and ONJ, and it will attempt to evaluate the association between features of ONJ and pharmacological, systemic, and site variables. Methods: Demographic, pharmacological, and clinical data from 18 RA patients with ONJ were collected and registered fr…

Malemedicine.medical_specialtymedicine.medical_treatmentOsteoporosisONJArthritis Rheumatoid03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansBisphosphonateONJ; Bisphosphonate; Denosumab; Jaw; Osteonecrosis; Osteoporosis; Rheumatoid arthritis; Dentistry (all); Otorhinolaryngology2734 Pathology and Forensic MedicineRheumatoid arthritisAdverse effectGeneral DentistryRheumatoid arthritiAgedBisphosphonate-associated osteonecrosis of the jawbusiness.industryOtorhinolaryngology2734 Pathology and Forensic MedicineOsteoporosiOsteonecrosis030206 dentistryBisphosphonateMiddle Agedmedicine.diseaseSurgeryDenosumabOtorhinolaryngologyJaw030220 oncology & carcinogenesisRheumatoid arthritisOsteonecrosiDentistry (all)OsteoporosisMethotrexateBisphosphonate-Associated Osteonecrosis of the JawFemaleDenosumabbusinessOsteonecrosis of the jawmedicine.drug
researchProduct

Osteonecrosis of the jaw related to everolimus and bisphosphonate: a unique case report?

2013

Osteonecrosis of the jaw (ONJ) is a rare but serious lesion of the jaw, characterized mainly by exposed necrotic bone;it is related to various drugs, usually used for treating patients with advanced malignancies. Drugs implicated in ONJ are: nitrogen-containing bisphosphonates (NBPs), denosumab, anti-angiogenic drugs (e.g bevacizumab, sunitinib,sorafenib) and the selective mammalian target of rapamycin mTOR, everolimus. Previous data regarding the combining of NBPs with antiangiogenic agents conflict with some reports (indicating a similar risk of ONJ compared with the use of NBPs alone1); other reports show significantly higher rates (18% vs 1% with NBPs alone) of the incidence of ONJ2. Th…

Settore MED/28 - Malattie OdontostomatologicheCase Reportosteonecrosis of the jaws everolimus
researchProduct

THE ROLE OF HIGH-DOSE VITAMIN D IN RISK REDUCTION OF OSTEONECROSIS OF THE JAW IN CANCER PATIENTS RECEIVING ZOLEDRONIC ACID

Osteonecrosis of the jaw (ONJ) is a serious complication of oncological patients after or during drug therapy, whose manifestations range from asymptomatic to aspects requiring extensive operative treatment and adversely affecting patient’s qualify of life. Taking in account that the lack of supplementation vitamin D causes hypovitaminosis, increasing bone renewal, losing bone mass, and in severe cases determing osteomalacia (one of the risk factors for ONJ) and that the probability of developing ONJ increases significantly during the first 3 years of treatment, the main objective of the present study is to assess whether the implementation of high-dose vitamin D in oncologic patients treat…

OSTEONECROSIS JAW VITAMIN D ZOLEDRONIC ACID CANCER
researchProduct

Dual localization of oral Kaposi’s sarcoma in HIV-negative patient: a rare case report

2016

Not available

Settore MED/28 - Malattie Odontostomatologichedual localization kaposi's sarcoma hiv case report
researchProduct